Comparative Pharmacology
Head-to-head clinical analysis: CONRAY 400 versus OMNIPAQUE 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY 400 versus OMNIPAQUE 300.
CONRAY 400 vs OMNIPAQUE 300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated radiocontrast agent that attenuates X-rays by blocking their passage, thereby enhancing radiographic contrast in imaging procedures.
Iodinated contrast agent that attenuates X-rays, providing vascular and tissue opacification by increasing the density of blood vessels and organs.
0.5-1.0 mL/kg (up to 150 mL total) intravenously, maximum 150 mL per procedure.
Intravenous: 1-2 mL/kg (300 mg I/mL) for contrast-enhanced CT; intra-arterial: 5-80 mL per injection depending on procedure; maximum total dose 4 mL/kg.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function. In patients with renal impairment, half-life may be prolonged significantly.
The terminal elimination half-life of iohexol in patients with normal renal function (creatinine clearance > 90 mL/min) is approximately 1.5 to 2 hours. In patients with renal impairment, the half-life is significantly prolonged (up to 30 hours or more in severe renal failure), necessitating dose adjustment and careful monitoring.
Primarily renal: >95% of administered dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion: negligible (<1%).
Omnipaque 300 (iohexol) is primarily eliminated unchanged by the kidneys via glomerular filtration. Renal excretion accounts for >95% of the administered dose within 24 hours in patients with normal renal function. Fecal excretion is negligible (<1%). Billiary excretion is minimal, with less than 0.1% recovered in bile or feces.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent